Investigator, Principal |
NCT05120895: An Observational Study Investigating the Change in Blood Cholesterol With Mevalotin® Tablet Administration in Korean Menopausal Women Aged 50 Years or More Who Require Treatment of Dyslipidemia |
|
|
| Active, not recruiting | N/A | 3300 | RoW | Mevalotin | Daiichi Sankyo, Daiichi Sankyo Korea Co., Ltd. | Dyslipidemia | 04/25 | 04/25 | | |
NCT05606094: Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia |
|
|
| Completed | N/A | 450 | RoW | | Daiichi Sankyo Co., Ltd. | Gastric Cancer | 11/23 | 11/23 | | |
NCT03866707: Epigenetic and Metabolomic Changes in Childhood Cancer Survivors |
|
|
| Terminated | N/A | 7 | US | One-time blood draw, Evaluation of CpG methylation, Metabolomic analysis | Wake Forest University Health Sciences | Childhood Cancer | 05/20 | 05/20 | | |
| Completed | N/A | 11 | US | Psychosocial intervention | Medical University of South Carolina | Aphasia, Stroke | 12/23 | 12/23 | | |
NCT06210776: A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH) |
|
|
| Recruiting | N/A | 800 | RoW | Trastuzumab deruxtecan, T-DXd | Daiichi Sankyo | HER2-positive Breast Cancer, HER2-low Breast Cancer, Breast Cancer, Advanced Cancer | 03/28 | 03/28 | | |
NCT04910048: Impact of a POPOP on Preoperative Health, Eligibility, and Clinical & Patient-Reported Outcomes in TJA |
|
|
| Active, not recruiting | N/A | 46 | US | POPOP (preoperative patient optimization program), 20Lighter, SOC (standard of care) | University of Arkansas | Osteoarthritis, Knee, Osteoarthritis, Hip, Avascular Necrosis, Rheumatoid Arthritis | 04/23 | 12/24 | | |
NCT06204900: A Post-marketing Study to Evaluate a Novel Surgical Monitoring Technique Using the EARP Nerve Cuff in TLIF Surgery. |
|
|
| Not yet recruiting | N/A | 30 | US | Nerve Cuff and Retractor System | Retropsoas Technologies, LLC | Undergoing a Single-level or Two-level TLIF Surgery | 06/24 | 08/24 | | |
ACAB, NCT04292405: Accuracy of Cardiac Acoustic Biomarkers Recorded by the Wearable Cardioverter Defibrillator |
|
|
| Recruiting | N/A | 60 | US | Wearable Cardioverter Defibrillator, AUDICOR AM | Zoll Medical Corporation | Heart Failure | 03/24 | 05/24 | | |
| Recruiting | N/A | 60 | US | BHmApp | William Beaumont Hospitals, University of Pennsylvania | Urinary Incontinence | 08/24 | 08/24 | | |
| Recruiting | N/A | 200 | Europe | | Chelsea and Westminster NHS Foundation Trust, ViiV Healthcare | HIV Infections, Gender Identity, Human Immunodeficiency Virus | 04/24 | 10/25 | | |
| Active, not recruiting | N/A | 70 | US | PQ Bypass System | Endologix | Peripheral Artery Diseases | 06/24 | 06/24 | | |
NCT03586414: MitoQ Supplementation and Cardiovascular Function in Healthy Men and Women |
|
|
| Active, not recruiting | N/A | 31 | US | MITOQUINOL MESYLATE then placebo, MitoQ, Mitoquinol methanesulfonate, Placebo, then MITOQUINOL MESYLATE | University of Colorado, Denver, University of Colorado Nutrition Obesity Research Center (NORC) | Diastolic Dysfunction | 07/25 | 08/25 | | |
NCT06361797: Varying Bone Marrow-Derived Mesenchymal Stem Cells Concentrations' Impact on Rotator Cuff Repair Outcomes |
|
|
| Not yet recruiting | N/A | 150 | US | Rotator cuff repair augmented with whole bone marrow, Whole bone marrow, Bone marrow aspirate, Rotator cuff repair augmented with concentrated bone marrow, Bone marrow-derived mesenchymal stem cells, Bone marrow concentrate | Johns Hopkins University, ON Foundation | Rotator Cuff Tears | 07/26 | 12/27 | | |
NCT06340503: Evaluating a Physical Activity Index for Assessment and Counseling for Breast and Colon Cancer Survivors |
|
|
| Recruiting | N/A | 20 | US | Research-grade accelerometer, National Comprehensive Cancer Network (NCCN) Education Materials, Garmin Vivofit activity tracker, Exercise Consultation Calls, Interview, Physical Activity Index Assessment (Intervention Arm), Physical Activity Index Assessment (Control Arm), Health Surveys | Wake Forest University Health Sciences, National Cancer Institute (NCI) | Breast Cancer, Colon Cancer | 07/25 | 08/25 | | |
NCT02945085: 3D Team Care for Cognitively Vulnerable Older Adults |
|
|
| Recruiting | N/A | 576 | US | Home Based Care Team, Telephone Based Care Team | UConn Health, Patient-Centered Outcomes Research Institute, University of Connecticut | Dementia, Depression, Delirium | 07/24 | 07/24 | | |
NCT04931251: Addressing Cancer-Related Financial Toxicity in Rural Oncology Care Settings |
|
|
| Recruiting | N/A | 780 | US | Financial Navigation | UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI) | Neoplasms, Carcinoma | 07/24 | 07/24 | | |
| Active, not recruiting | N/A | 80 | US | Gaming in a virtual environment | Yale University, National Heart, Lung, and Blood Institute (NHLBI) | Cardiovascular Diseases | 07/25 | 07/25 | | |
NCT04927052: A Study to Evaluate the Safety and Efficacy of Revanesse Shape + With Lidocaine Versus Juvederm Voluma With Lidocaine for the Correction of Age-Related Midface Volume Deficit / Lipoatrophy at 6 and 12 Months Post-treatment |
|
|
| Completed | N/A | 136 | Canada | Revanesse Shape + with Lidocaine, Juvederm Voluma with Lidocaine. | Prollenium Medical Technologies Inc. | Volume Deficit in the Mid-face | 08/23 | 08/23 | | |
| Not yet recruiting | N/A | 16 | US | KeraStat cream, M-PART Assessments via MyCap, Clinical Assessments, Feedback phone interview | Wake Forest University Health Sciences, National Cancer Institute (NCI) | Radiation Dermatitis | 08/26 | 08/26 | | |
| Active, not recruiting | N/A | 5000 | RoW | Edoxaban | Daiichi Sankyo, Inc., Daiichi Sankyo (China) Holdings Co., Ltd. | Non-valvular Atrial Fibrillation | 10/24 | 10/24 | | |
ROCK-RT, NCT05169177: Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy |
|
|
| Recruiting | N/A | 50 | RoW | | University of Sydney, Calvary Mater Newcastle, Australia, Western Sydney Local Health District, Austin Health, Peter MacCallum Cancer Centre, Australia, Princess Alexandra Hospital, Brisbane, Australia | Liver Neoplasm | 10/24 | 10/26 | | |
NCT01336790: International Lymphatic Disease and Lymphedema Registry |
|
|
| Recruiting | N/A | 5000 | US | | Stanford University, Lymphatic Education & Research Network | Lymphedema | 12/24 | 12/25 | | |
NCT05531357: Physiologic Mechanisms Underlying Ovarian Follicular Waves During the Menstrual Cycle |
|
|
| Completed | N/A | 50 | Canada | Transvaginal ultrasound scans, Finger-prick blood sampling for dried blood spots, Urine sampling, Venipunctures | University of Saskatchewan, Ansh Labs | Reproductive Issues | 03/24 | 03/24 | | |
| Recruiting | N/A | 200 | US | Education and counseling, Education | Georgetown University | Breast Cancer | 12/24 | 12/25 | | |
NCT05689190: Non-invasive Flow Measurements in Patients With Lower Extremity Arterial Disease (LEAD) |
|
|
| Recruiting | N/A | 30 | Europe | | Philips Clinical & Medical Affairs Global, Leiden University Medical Center | Lower Extremity Arterial Disease | 12/24 | 12/24 | | |
NCT05862467: A Pilot Participatory Program Evaluation of a Virtual Trauma Support Program for Autistic Adults |
|
|
| Recruiting | N/A | 30 | US | Written Exposure Therapy (WET) via telehealth | University of Wyoming | Autism, Trauma, Posttraumatic Stress Disorder, Posttraumatic Stress Symptom | 05/25 | 05/25 | | |
NCT04635111: A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment |
|
|
| Recruiting | N/A | 30 | US | TURALIO™ | Daiichi Sankyo, Inc. | Hepatotoxicity, Tenosynovial Giant Cell Tumor | 06/25 | 03/36 | | |
| Recruiting | N/A | 198 | US | Dietary Intervention Classes | University of South Carolina | Diabetes Mellitus, Type 2, Obesity | 12/25 | 03/26 | | |
MILOS, NCT04579367: Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia |
|
|
| Recruiting | N/A | 5000 | Europe | Bempedoic acid and/or its fixed-dose combination with ezetimibe | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Hypercholesterolemia, Mixed Dyslipidemia | 09/25 | 09/25 | | |
NCT06054412: An Adjunctive Neurofeedback Training Program to Enhance Wellness Among Trauma-Exposed Postpartum Mothers |
|
|
| Recruiting | N/A | 20 | US | Neuroptimal (Zengar, Inc.) Neurofeedback | Wayne State University | Well-Being, Psychological, Dissociation, Maternal Care Patterns, Maternal Behavior, Maternal Distress, Mood Disturbance, Emotional Regulation, Post Traumatic Stress Disorder | 09/25 | 03/26 | | |
| Active, not recruiting | N/A | 7 | US | Actual device PFO closure, GORE® CARDIOFORM Septal Occluder, Thienopyridine (clopidogrel or prasugrel), Plavix, Effient, Sham device PFO closure | W.L.Gore & Associates | Migraine, Patent Foramen Ovale, PFO - Patent Foramen Ovale | 12/25 | 08/26 | | |
SILVERCARE_AF, NCT05804747: A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation |
|
|
| Recruiting | N/A | 1100 | RoW | Edoxaban | Daiichi Sankyo, Daiichi Sankyo Korea Co., Ltd. | Atrial Fibrillation | 12/25 | 12/25 | | |
LEARN, NCT05184790: Learning Environment for Artificial Intelligence in Radiotherapy New Technology |
|
|
| Not yet recruiting | N/A | 300 | RoW | | University of Sydney, Princess Alexandra Hospital, Brisbane, Australia, Calvary Mater Newcastle, Australia, Western Sydney Local Health District, Austin Health, Peter MacCallum Cancer Centre, Australia | Arrhythmias, Cardiac, Breast Cancer, Prostatic Cancer, Brain Cancer, Kidney Cancer, Head and Neck Cancer, Liver Cancer, Pancreatic Cancer, Spinal Neoplasm | 01/26 | 01/26 | | |
NCT05022862: Economic Incentives and vDOT for Latent Tuberculosis Infection |
|
|
| Recruiting | N/A | 399 | US | Usual Care, Video Directly Observed Therapy alone, Video Directly Observed Therapy plus Financial Incentives | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) | Latent Tuberculosis | 04/26 | 10/26 | | |
NCT05993234: A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY) |
|
|
| Recruiting | N/A | 257 | Europe | Trastuzumab deruxtecan, T-DXd, ENHERTU® | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma | 12/26 | 09/27 | | |
| Recruiting | N/A | 1350 | Europe | Trastuzumab deruxtecan, T-DXd | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer | 06/27 | 09/28 | | |
NCT05636397: Safety and PK-PD Study of Oral L-CIT in Preterm Infants With BPD±PH and NEC |
|
|
| Recruiting | N/A | 60 | Canada | L-Citrulline | The Hospital for Sick Children | BPD - Bronchopulmonary Dysplasia, Pulmonary Hypertension, NEC | 12/27 | 03/28 | | |
NCT05181163: Biofilm Formation and Antibiotic Sensitivity Patterns |
|
|
| Not yet recruiting | N/A | 100 | NA | swab | Sohag University | Orthopedic Surgery | 07/22 | 01/23 | | |
Richardson, Lynne D |
| Active, not recruiting | 4 | 3239 | Europe, US, RoW | theraputic heparin, unfractionated heparin, Enoxaparin, Dalteparin, Tinzaparin, Heparin, prophylactic heparin, enoxaparin, dalteparin, Fondparinux, P2Y12, Ticagrelor, Prasugrel, Clopidogrel, Crizanlizumab Injection, SGLT2 inhibitor, dapagliflozin, empagliflozin, canagliflozin, ertugliflozin | Matthew Neal MD, National Heart, Lung, and Blood Institute (NHLBI) | Covid19 | 08/23 | 06/24 | | |
| Recruiting | N/A | 300 | US | | Stanford University, National Heart, Lung, and Blood Institute (NHLBI) | Asthma | 07/24 | 07/24 | | |
Pinney, Sean |
| Recruiting | N/A | 80 | US | Satera GSN Ablation, Sham Control | Axon Therapies, Inc. | Heart Failure With Preserved Ejection Fraction | 04/22 | 03/23 | | |
| Recruiting | N/A | 372 | US | Aquadex Smartflow® System, IV Loop Diuretics | Nuwellis, Inc. | Heart Failure (for Example, Fluid Overload) | 07/25 | 10/25 | | |
LUX-Dx TRENDS, NCT04790344: Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System. |
|
|
| Active, not recruiting | N/A | 525 | US | Investigational LUX-Dx ICM Implant | Boston Scientific Corporation | Heart Failure | 05/26 | 06/26 | | |
Guttman, Emma |
| Active, not recruiting | 4 | 44 | US | Dupilumab, Dupixent, Placebo | Icahn School of Medicine at Mount Sinai, Regeneron Pharmaceuticals, Sanofi | Keloid | 09/24 | 04/25 | | |
LEADS, NCT05436535: Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis |
|
|
| Recruiting | 4 | 600 | US | Dupilumab, Dupixent, Vanicream- Dupilumab-naïve, Triamcinolone Acetonide, Hydrocortisone, Vanicream- Active, Vanicream- Experienced Dupilumab | National Institute of Allergy and Infectious Diseases (NIAID) | Atopic Dermatitis | 05/25 | 10/25 | | |
NCT05608499: Duobrii Treatment of Acne Keloidalis Nuchae (AKN) |
|
|
| Recruiting | 3 | 30 | US | Duobrii, halobetasol propionate and tazarotene, Placebo, Bryhali, halobetasol propionate | Icahn School of Medicine at Mount Sinai, Bausch Health Americas, Inc. | Acne Keloidalis Nuchae, AKN | 10/24 | 10/24 | | |
NCT05076006: Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia |
|
|
| Completed | 2 | 50 | US | PF-06700841, Brepocitinib, Placebo | Emma Guttman, Pfizer | Cicatricial Alopecia | 09/23 | 09/23 | | |
NCT06373458: Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy |
|
|
| Recruiting | 2 | 30 | US | Ritlecitinib | Icahn School of Medicine at Mount Sinai, Pfizer | Keloid | 03/26 | 05/26 | | |
| Recruiting | 1 | 40 | US | Abrocitinib | Icahn School of Medicine at Mount Sinai | Food Allergy | 10/24 | 10/24 | | |
NCT01782703: Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis |
|
|
| Recruiting | N/A | 930 | US | | Northwestern University, Rockefeller University, Icahn School of Medicine at Mount Sinai | Atopic Dermatitis, Eczema | 12/25 | 12/25 | | |
NCT03417856: Defining the Skin and Blood Biomarkers of Ichthyosis |
|
|
| Recruiting | N/A | 200 | US | | Northwestern University, Icahn School of Medicine at Mount Sinai, Galderma R&D | Ichthyosis, Netherton Syndrome | 12/25 | 12/25 | | |
| Recruiting | N/A | 15000 | Europe, Canada, US | | Target PharmaSolutions, Inc. | Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria | 12/50 | 12/50 | | |
Komtebedde, Jan |
| Active, not recruiting | N/A | 10 | US, RoW | IASD implant | Corvia Medical | Heart Failure | 12/26 | 12/27 | | |
Cammack, Sam |
NCT04831125: Conduction System Pacing International Registry (CONSPIRE) |
|
|
| Recruiting | N/A | 1000 | Europe, US | Data collection | University of Chicago, Biotronik SE & Co. KG | Bradyarrhythmia, Heart Failure | 04/25 | 04/25 | | |
Lewis, Meredith |
| Completed | 3 | 407 | Europe, Canada, US, RoW | Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir | Eiger BioPharmaceuticals | Hepatitis Delta Virus | 10/22 | 03/23 | | |
LIMT-2, NCT05070364: Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV |
|
|
| Active, not recruiting | 3 | 150 | Europe, US, RoW | Peginterferon Lambda-1a, Lambda, Peginterferon Lambda, Pegylated Interferon Lambda | Eiger BioPharmaceuticals | Hepatitis Delta Virus | 06/24 | 01/25 | | |
Tokita, Joji |
| Recruiting | 1/2 | 30 | US | Metformin + Standard of Care, Placebo + Standard of Care | Yale University, United States Department of Defense | Focal Segmental Glomerulosclerosis | 11/27 | 11/27 | | |
Carrara, Gina |
| Active, not recruiting | 2 | 400 | US | Pfizer-BioNTech COVID-19 Vaccine 2023-2024, mRNA COVID-19 vaccine, BNT162b2 mRNA COVID-19 vaccine, SARS-CoV-2 RNA vaccine, Comirnaty, Moderna COVID-19 Vaccine 2023-2024, Moderna COVID-19 vaccine, SARS-CoV-2 vaccine, Spikevax, SOC IS Regimen, Standard of Care transplant immunosuppression regimen, Immunosuppression (IS), mycophenolate mofetil (MMF) or equivalent, tacrolimus, SOC IS Reduction, Standard of Care (SOC) transplant immunosuppression regimen, Immunosuppression (IS) Reduction | National Institute of Allergy and Infectious Diseases (NIAID), PPD, Johns Hopkins University | Kidney Transplant Recipients, Liver Transplant Recipients | 02/24 | 03/25 | | |
Rana, Meena M |
| Active, not recruiting | 2 | 400 | US | Pfizer-BioNTech COVID-19 Vaccine 2023-2024, mRNA COVID-19 vaccine, BNT162b2 mRNA COVID-19 vaccine, SARS-CoV-2 RNA vaccine, Comirnaty, Moderna COVID-19 Vaccine 2023-2024, Moderna COVID-19 vaccine, SARS-CoV-2 vaccine, Spikevax, SOC IS Regimen, Standard of Care transplant immunosuppression regimen, Immunosuppression (IS), mycophenolate mofetil (MMF) or equivalent, tacrolimus, SOC IS Reduction, Standard of Care (SOC) transplant immunosuppression regimen, Immunosuppression (IS) Reduction | National Institute of Allergy and Infectious Diseases (NIAID), PPD, Johns Hopkins University | Kidney Transplant Recipients, Liver Transplant Recipients | 02/24 | 03/25 | | |